OncoMatch/Clinical Trials/NCT04573231
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Is NCT04573231 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies 18F-DCFPyL for breast cancer.
Treatment: 18F-DCFPyL — The purpose of this research is to determine the expression of prostate specific membrane antigen (PSMA) in human epidermal growth factor receptor 2 (HER2)-negative, androgen receptor (AR)-positive metastatic breast cancer, and to determine its role in resistance to the anti-androgen, bicalutamide. The investigators hypothesize that PSMA expression will correlate with resistance to anti-androgen therapies, as has been documented in prostate cancer, and this can be used to select patients most likely to benefit from these therapies in future clinical trials. 15 people with HER2-negative, AR-positive metastatic breast cancer will be enrolled and be on study for about 3 days.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) wild-type
HER2-negative
Required: AR any tested (≥ 10%)
AR expression of ≥ 10%
Disease stage
Metastatic disease required
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Wisconsin School of Medicine and Public Health · Madison, Wisconsin
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify